.jpeg)
2026-08-28 07:03:42
Elagolix (brand name Orilissa) is FDA-approved for moderate to severe pain caused by endometriosis, including painful periods. This article explains its mechanism, who should use it, and safety limits.
2026-08-28 06:59:42
Bosentan is an endothelin receptor antagonist used for pulmonary arterial hypertension (PAH), not common high blood pressure. This article explains the difference and precautions for concurrent use.
2026-08-28 06:56:21
Letermovir is used to prevent cytomegalovirus (CMV) infection in transplant patients. This article details the administration methods for tablets and granules, dosage requirements, and drug interactions, emphasizing the importance of following medical advice.
2026-08-28 06:51:52
In August 2026, the U.S. FDA granted accelerated approval to daraxonrasib (Rasonque), an oral RAS(ON) inhibitor developed by Revolution Medicines. The drug significantly improves survival in metastatic pancreatic cancer, reshaping the treatment landscape.
2026-08-27 07:16:18
Brensocatib (Brinsupri) is the first FDA-approved disease-modifying therapy for non-cystic fibrosis bronchiectasis. Based on the ASPEN Phase 3 trial, it significantly reduces annual exacerbation rates and slows lung function decline. This article details patient selection, efficacy data, and safety management.
2026-08-27 07:05:19
Mirdametinib is a MEK1/2 inhibitor approved by the FDA for symptomatic, inoperable plexiform neurofibromas in patients with NF1 aged 2 years and older. This article explains its mechanism, ReNeu trial data, and targeted therapy value.
2026-08-27 05:38:45
In August 2026, the FDA approved zanidatamab (Ziihera) in combination with tislelizumab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, achieving a median OS of 26.4 months. This article details the clinical data, indications, safety warnings, and dosing guidelines.
2026-08-26 07:44:33
Acalabrutinib is a selective oral BTK inhibitor for B-cell malignancies like CLL. This article outlines its twice-daily dosing, the timeline for efficacy evaluation, and the importance of adherence.
2026-08-26 07:21:45
Osimertinib (brand name: TAGRISSO) is a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutant NSCLC. This article reviews its clinical efficacy, food administration advice, tablet handling, and key safety precautions.
2026-08-26 07:14:21
Bosutinib is a BCR-ABL/SRC tyrosine kinase inhibitor primarily indicated for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This article reviews its established indications, investigational use in autosomal dominant polycystic kidney disease (ADPKD), and critical safety boundaries.
2026-08-26 07:10:57
Ceritinib (brand name: Zykadia) is a second-generation oral ALK tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. This guide outlines the recommended 450mg once-daily dosing with food, dose modification principles, and missed-dose protocols to support safe and effective treatment.
2026-08-26 07:08:08
Ruxolitinib is a JAK1/JAK2 inhibitor used in myelofibrosis and other myeloproliferative neoplasms. This guide outlines drug interactions involving CYP3A4/CYP2C9, dosing considerations in hepatic impairment, and safety precautions during infection.
